Fluticasone propionate - Glaxo Wellcome

Drug Profile

Fluticasone propionate - Glaxo Wellcome

Alternative Names: Flixotide; Flixotide Evohaler; Flixotide Nebules

Latest Information Update: 27 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Glaxo Wellcome SA
  • Class Androstadienes; Anti-inflammatories; Antiallergics; Antiasthmatics; Glucocorticoids; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Asthma

Most Recent Events

  • 28 Sep 2016 Discontinued - Phase-II for Asthma in New Zealand (Inhalation)
  • 03 Aug 2016 Glaxo Wellcome initiates a phase III trial in Asthma (Prevention) in China (Inhalation) (EudraCT2015-004870-14)
  • 19 May 2016 Launched for Asthma (Prevention) in Israel (Inhalation) before May 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top